The Growth of the small-cell lung cancer market is expected to be driven by increasing incident cases of SCLC, mainly due to an increase in the geriatric population, the expected entry of potential premium price emerging therapies, and the expected readily uptake of currently approved immunotherapies across 7MM..

预计小细胞肺癌市场的增长将受到SCLC事件增加的推动，这主要是由于老年人群的增加，潜在溢价新兴疗法的预期进入以及目前预期的容易接受批准7MM的免疫疗法。。

LAS VEGAS, Oct. 4, 2023 /PRNewswire/ -- DelveInsight's Small-Cell Lung Cancer Market Insights report includes a comprehensive understanding of current treatment practices, small-cell lung cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan]..

拉斯维加斯，2023年10月4日/PRNewswire/-DelveInsight的小细胞肺癌市场见解报告包括对当前治疗实践，小细胞肺癌新兴药物，个体治疗的市场份额以及当前和预测的全面了解2019年至2032年的市场规模，分为7MM[美国，EU-4（意大利，西班牙，法国和德国），英国和日本]）。。

Key Takeaways from the Small-Cell Lung Cancer Market Report

小细胞肺癌市场报告的主要收获

According to DelveInsight analysis, the small-cell lung cancer market is anticipated to increase at a significant CAGR during the forecast period due to the expected launch of emerging therapies.

根据DelveInsight分析，由于预计将推出新兴疗法，预计在预测期间小细胞肺癌市场将以显着的CAGR增长。

According to DelveInsight's analysis, there is a gender difference in the disease. It was seen that the SCLC occurs more frequently in the male population as compared to females.

根据DelveInsight的分析，该疾病存在性别差异。可以看出，与女性相比，SCLC在男性人群中的发生频率更高。

Leading small-cell lung cancer companies such as Medicine Invention Design, Inc, Advenchen Laboratories, LLC, Bristol-Myers Squibb, Clovis Oncology, Inc., Cardiff Oncology, Legend Biotech USA Inc, Bellicum Pharmaceuticals, Genentech, Inc., Phanes Therapeutics, AbbVie, Amgen, Daiichi Sankyo, Inc., HiberCell, Inc., Hoffmann-La Roche, Harpoon Therapeutics, BioNTech SE, Boehringer Ingelheim, Chipscreen Biosciences, Ltd., Andarix Pharmaceuticals, Telix International Pty Ltd, Syros Pharmaceuticals, Jacobio Pharmaceuticals Co., Ltd., Cybrexa Therapeutics, and others are developing novel small-cell lung cancer drugs that can be available in the small-cell lung cancer market in the coming years..

领先的小细胞肺癌公司，如Medicine Invention Design，Inc，Advenchen Laboratories，LLC，Bristol-Myers Squibb，Clovis Oncology，Inc.，Cardiff Oncology，Legend Biotech USA Inc，Bellicum Pharmaceuticals，Genentech，Inc.，Phanes Therapeutics，AbbVie，Amgen，Daiichi-Sankyo，Inc.，HiberCell，Inc.，Hoffmann-La Roche，Harpoon Therapeutics，BioNTech SE，Boehringer Ingelheim，Chipscreen Biosciences，Ltd.，Andarix Pharmaceuticals，Telix International Pty Ltd，Syros Pharmaceuticals，Jacobio Pharmaceuticals Co.，Ltd.，Cybrexa Therapeutics等正在开发可用于小细胞肺癌的新型小细胞肺癌药物。未来几年的肺癌市场。。

Some key therapies for small-cell lung cancer treatment include ETOPOSIDE, AL8326, Combination immunotherapy with Ipilimumab and Nivolumab, Rucaparib and Nivolumab, Onvansertib, LB2102, iC9.GD2.CAR.IL-15 T Infusion, Bevacizumab, PT217, ABBV-011, AMG 404, Ifinatamab Deruxtecan (I-DXd), HC-5404-FU, RO7616789, HPN328, BNT411, BI 764532, Chiauranib, Rhenium (Re 188 P2045, BAY86-5284), 89Zr-DFO-girentuximab, SY-5609, JAB-2485, CBX-12, and others..

小细胞肺癌治疗的一些关键疗法包括依托泊苷，AL8326，与Ipilimumab和Nivolumab联合免疫治疗，Rucaparib和Nivolumab，Onvansertib，LB2102，iC9.GD2.CAR.IL-15 T输注，贝伐单抗，PT217，ABBV-011，AMG 404，Ifinatamab Deruxtecan（I-DXd），HC-5404-FU，RO7616789，HPN328，BNT411，BI 764532，Chiauranib，Rhenium（Re 188 P2045，BAY86-5284），89Zr-DFO-girentuximab，SY-5609，JAB-2485，CBX-12等。。

Discover which therapies are expected to grab the major small-cell lung cancer market share @ Small-Cell Lung Cancer Market Report

发现哪些疗法有望占据主要的小细胞肺癌市场份额@小细胞肺癌市场报告

Small-Cell Lung Cancer Overview

小细胞肺癌概述

Small-cell lung cancer (SCLC) is a highly aggressive and fast-growing form of lung cancer. It accounts for about 10-15% of all lung cancer cases. SCLC is closely linked to smoking, with the majority of patients being current or former smokers. The primary cause of small-cell lung cancer is tobacco smoking.

小细胞肺癌（SCLC）是一种高度侵袭性和快速增长的肺癌形式。它约占所有肺癌病例的10-15%。SCLC与吸烟密切相关，大多数患者是现在或以前的吸烟者。小细胞肺癌的主要原因是吸烟。

The carcinogens in tobacco smoke can damage the cells lining the airways, leading to genetic mutations that trigger the development of cancer..

烟草烟雾中的致癌物质会破坏气道内的细胞，导致引发癌症发展的基因突变。。

Symptoms of SCLC are often subtle in the early stages, which can make diagnosis challenging. Common symptoms include persistent cough, chest pain, shortness of breath, fatigue, and unexplained weight loss. Additionally, some patients may experience symptoms related to the cancer spreading to other parts of the body, such as bone pain or neurological symptoms..

SCLC的症状在早期阶段通常很微妙，这可能使诊断具有挑战性。常见症状包括持续咳嗽，胸痛，呼吸短促，疲劳和不明原因的体重减轻。此外，一些患者可能会出现与癌症扩散到身体其他部位相关的症状，如骨痛或神经系统症状。。

Diagnosing SCLC typically involves a combination of imaging tests like CT scans and X-rays to visualize the tumor, as well as a biopsy to confirm the cancer type. The biopsy may involve removing a small sample of tissue from the lung for examination. Once diagnosed, staging tests are performed to determine the extent of cancer spread, which is critical for treatment planning..

诊断SCLC通常涉及成像测试的组合，例如CT扫描和X射线以显现肿瘤，以及活组织检查以确认癌症类型。活组织检查可能涉及从肺中取出少量组织样本进行检查。一旦确诊，进行分期检查以确定癌症扩散的程度，这对治疗计划至关重要。。

Small-Cell Lung Cancer Epidemiology Segmentation

小细胞肺癌流行病学细分

The small-cell lung cancer epidemiology section provides insights into the historical and current small-cell lung cancer patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. .

小细胞肺癌流行病学部分提供有关历史和当前小细胞肺癌患者库的见解以及个别七大国家的预测趋势。它通过探索众多研究和主要意见领袖的观点，有助于认识当前和预测趋势的原因。 .

The small-cell lung cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

小细胞肺癌市场报告提供了2019-2032年研究期间的流行病学分析，分为7MM分为：

SCLC Incidence Cases

SCLC发病病例

SCLC Gender-specific Incidence

SCLC性别特异性发病率

SCLC Age-specific Incidence

SCLC年龄特异性发病率

SCLC Stage-Specific Incidence

SCLC阶段特异性发病率

Line-wise Treatment of Extensive-Stage SCLC

广泛期小细胞肺癌的一线治疗

Small-Cell Lung Cancer Treatment Market

小细胞肺癌治疗市场

The primary treatment options for SCLC typically involve a combination of chemotherapy and radiation therapy. Due to its rapid growth and tendency to spread quickly, SCLC is often treated aggressively from the outset. Chemotherapy involves the administration of potent drugs to target and kill cancer cells throughout the body.

SCLC的主要治疗选择通常涉及化疗和放疗的组合。由于其快速增长和快速传播的趋势，SCLC通常从一开始就积极对待。化学疗法涉及施用有效药物以靶向和杀死整个身体的癌细胞。

In some cases, chemotherapy may be given before surgery to shrink tumors and make them more operable. Radiation therapy, on the other hand, uses high-energy radiation beams to target and destroy cancer cells in the lungs. Additionally, immunotherapy and targeted therapies are being explored as potential treatment options for SCLC.

在某些情况下，可以在手术前给予化疗以缩小肿瘤并使其更可行。另一方面，放射治疗使用高能辐射束来靶向和破坏肺部的癌细胞。此外，正在探索免疫疗法和靶向疗法作为SCLC的潜在治疗选择。

Immunotherapy drugs, such as checkpoint inhibitors, are increasingly being investigated and used in the treatment of SCLC. These drugs work by enhancing the body's immune system to recognize and attack cancer cells. Immunotherapy has shown promise in some patients with advanced SCLC..

免疫治疗药物，如检查点抑制剂，越来越多地被研究并用于治疗SCLC。这些药物通过增强身体的免疫系统来识别和攻击癌细胞。免疫治疗在一些晚期小细胞肺癌患者中显示出前景。。

While surgery is not typically the first-line treatment for SCLC due to its aggressive nature and propensity to spread early, it may be considered in some cases, especially if the cancer is detected at an early stage and is confined to a small area of the lung. Surgical options can include the removal of the tumor and possibly nearby lymph nodes.

虽然由于其侵袭性和早期传播倾向，手术通常不是小细胞肺癌的一线治疗方法，但在某些情况下可以考虑手术，特别是如果癌症在早期被发现并局限于肺部的一小部分区域。手术选择可以包括切除肿瘤和可能的附近淋巴结。

The choice of treatment depends on the stage of the cancer, the overall health of the patient, and other individual factors, and it is typically determined through a collaborative effort between the patient and their medical team. Despite its challenges, ongoing research offers hope for improved treatments and outcomes for individuals diagnosed with SCLC..

治疗的选择取决于癌症的阶段，患者的整体健康状况以及其他个体因素，并且通常通过患者与其医疗团队之间的协作努力来确定。尽管面临挑战，但正在进行的研究为诊断为SCLC的个体改善治疗和预后提供了希望。。

To know more about small-cell lung cancer treatment, visit @ Small-Cell Lung Cancer Treatment Drugs

要了解更多关于小细胞肺癌治疗的信息，请访问@小细胞肺癌治疗药物

Key Small-Cell Lung Cancer Therapies and Companies

关键的小细胞肺癌治疗和公司

ETOPOSIDE: Medicine Invention Design, Inc

依托泊苷：医学发明设计公司

AL8326: Advenchen Laboratories, LLC

AL8326:Adventhen Laboratories，LLC

Combination immunotherapy with Ipilimumab and Nivolumab: Bristol-Myers Squibb

Ipilimumab和Nivolumab联合免疫治疗：Bristol-Myers Squibb

Rucaparib and Nivolumab: Clovis Oncology, Inc.

Rucaparib和Nivolumab:Clovis Oncology，Inc。

Onvansertib: Cardiff Oncology

Onvansertib：卡迪夫肿瘤学

LB2102: Legend Biotech USA Inc

LB2102：传奇生物技术美国公司

iC9.GD2.CAR.IL-15 T Infusion: Bellicum Pharmaceuticals

iC9.GD2.CAR.IL-15 T输液：Bellicum Pharmaceuticals

Bevacizumab: Genentech, Inc.

瓦克西珠单抗：基因泰克股份有限公司。

PT217: Phanes Therapeutics

PT217:Phanes疗法

ABBV-011: AbbVie

ABBV-011:AbbVie

AMG 404: Amgen

AMG 404：安进

Ifinatamab Deruxtecan (I-DXd): Daiichi Sankyo, Inc.

Ifinatamab Deruxtecan（I-DXd）：Daiichi Sankyo，股份有限公司。

HC-5404-FU: HiberCell, Inc.

HC-5404-FU:HiberCell，股份有限公司。

RO7616789: Hoffmann-La Roche

RO7616789:Hoffmann-La Roche

HPN328: Harpoon Therapeutics

HPN328：鱼叉疗法

BNT411: BioNTech SE

BNT411:BioNTech SE

BI 764532: Boehringer Ingelheim

BI 764532:勃林格殷格翰

Chiauranib: Chipscreen Biosciences, Ltd.

Chiauranib:Chipscreen Biosciences，Ltd。

Rhenium (Re 188 P2045, BAY86-5284): Andarix Pharmaceuticals

Rhenium（Re 188 P2045，BAY86-5284）：Andarix Pharmaceuticals

89Zr-DFO-girentuximab: Telix International Pty Ltd

89Zr DFO girentuximab:Telix International Pty Ltd

SY-5609: Syros Pharmaceuticals

SY-5609:Syros Pharmaceuticals

JAB-2485: Jacobio Pharmaceuticals Co., Ltd.

JAB-2485：雅各比制药有限公司

CBX-12: Cybrexa Therapeutics

CBX-12：Cybrexa Therapeutics

Learn more about the FDA-approved drugs for small-cell lung cancer @ Drugs for Small-Cell Lung Cancer Treatment

了解更多关于FDA批准的小细胞肺癌药物@用于小细胞肺癌治疗的药物

Small-Cell Lung Cancer Market Dynamics

小细胞肺癌市场动态

Small-cell lung cancer market dynamics have been characterized by a complex interplay of factors. Historically, SCLC has presented significant challenges due to its aggressive nature and limited treatment options. However, recent years have witnessed notable shifts in this landscape. Advances in molecular biology and genomics have deepened our understanding of SCLC, leading to the identification of potential biomarkers and targeted therapies.

小细胞肺癌市场动态的特点是复杂的因素相互作用。从历史上看，SCLC由于其侵略性和有限的治疗选择而提出了重大挑战。然而，近年来，这一格局发生了显着变化。分子生物学和基因组学的进步加深了我们对SCLC的理解，从而确定了潜在的生物标志物和靶向治疗方法。

This has injected fresh optimism into the market, as pharmaceutical companies intensify their efforts to develop more effective treatments. .

随着制药公司加大努力开发更有效的治疗方法，这给市场带来了新的乐观情绪。 .

Additionally, the rising prevalence of smoking cessation campaigns and early detection strategies has the potential to alter the incidence and stage distribution of SCLC, further influencing market dynamics. Nevertheless, the SCLC market remains highly competitive, with evolving clinical trial landscapes and a need for innovative approaches to improve patient outcomes and quality of life.

此外，戒烟运动和早期发现策略的日益普及有可能改变小细胞肺癌的发病率和阶段分布，进一步影响市场动态。尽管如此，SCLC市场仍然具有很强的竞争力，随着临床试验环境的不断发展以及对改善患者预后和生活质量的创新方法的需求。

As research continues to unravel the complexities of this disease, the SCLC market is likely to witness ongoing transformations, making it a dynamic and closely watched sector within oncology..

随着研究不断解开这种疾病的复杂性，SCLC市场可能会看到持续的转变，使其成为肿瘤学领域一个动态且备受关注的领域。。

However, several factors may impede the growth of the SCLC market. One substantial barrier is the intrinsic heterogeneity of SCLC tumors. This complexity has made it difficult to identify uniform treatment approaches, hindering the development of targeted therapies. Additionally, SCLC is often diagnosed at an advanced stage, which limits the curative potential of treatments and adds to the complexity of managing the disease..

但是，有几个因素可能会阻碍SCLC市场的增长。一个实质性障碍是SCLC肿瘤的内在异质性。这种复杂性使得难以确定统一的治疗方法，阻碍了靶向治疗的发展。此外，SCLC通常被诊断为晚期，这限制了治疗的治愈潜力，并增加了治疗疾病的复杂性。。

Furthermore, regulatory hurdles and clinical trial design complexities slow down the introduction of innovative therapies. The stringent regulatory environment for cancer drugs demands robust clinical evidence, which can delay the approval and availability of new treatments. Patient awareness and access to early detection methods also pose barriers.

此外，监管障碍和临床试验设计的复杂性减缓了创新疗法的引入。癌症药物的严格监管环境需要强有力的临床证据，这可能会延迟新疗法的批准和可用性。患者意识和获得早期检测方法也构成障碍。

Effective smoking cessation campaigns and screening programs are essential for reducing SCLC incidence and improving outcomes, but these initiatives may not be uniformly accessible or widely adopted..

有效的戒烟运动和筛查计划对于降低小细胞肺癌的发病率和改善预后至关重要，但这些举措可能无法统一获得或广泛采用。。

Report Metrics

报告指标

Details

细节

Study Period

学习期

2019–2032

2019–2032

Coverage

新闻报道

7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]

7MM[美国、欧盟4国（德国、法国、意大利和西班牙）、英国和日本]

Key Small-Cell Lung Cancer Companies

关键的小细胞肺癌公司

Medicine Invention Design, Inc, Advenchen Laboratories, LLC, Bristol-Myers Squibb, Clovis Oncology, Inc., Cardiff Oncology, Legend Biotech USA Inc, Bellicum Pharmaceuticals, Genentech, Inc., Phanes Therapeutics, AbbVie, Amgen, Daiichi Sankyo, Inc., HiberCell, Inc., Hoffmann-La Roche, Harpoon Therapeutics, BioNTech SE, Boehringer Ingelheim, Chipscreen Biosciences, Ltd., Andarix Pharmaceuticals, Telix International Pty Ltd, Syros Pharmaceuticals, Jacobio Pharmaceuticals Co., Ltd., Cybrexa Therapeutics, and others .

医学发明设计有限公司，Advenchen Laboratories，LLC，Bristol-Myers Squibb，Clovis Oncology，Inc.，Cardiff Oncology，Legend Biotech USA Inc，Bellicum Pharmaceuticals，Genentech，Inc.，Phanes Therapeutics，AbbVie，Amgen，Daiichi Sankyo，Inc.，HiberCell，Inc.，Hoffmann-La Roche，Harpoon Therapeutics，BioNTech SE，Boehringer Ingelheim，Chipscreen Biosciences，Ltd.，Andarix Pharmac，Telix International Pty Ltd，Syros Pharmaceuticals，Jacobio Pharmaceuticals Co.，Ltd.，Cybrexa Therapeutics等。

Key Small-Cell Lung Cancer Therapies

关键的小细胞肺癌治疗

ETOPOSIDE, AL8326, Combination immunotherapy with Ipilimumab and Nivolumab, Rucaparib and Nivolumab, Onvansertib, LB2102, iC9.GD2.CAR.IL-15 T Infusion, Bevacizumab, PT217, ABBV-011, AMG 404, Ifinatamab Deruxtecan (I-DXd), HC-5404-FU, RO7616789, HPN328, BNT411, BI 764532, Chiauranib, Rhenium (Re 188 P2045, BAY86-5284), 89Zr-DFO-girentuximab, SY-5609, JAB-2485, CBX-12, and others .

依托泊苷，AL8326，联合免疫治疗与伊利单抗和尼洛单抗、Rucaparib和尼洛单抗、Onvansertib，LB2102，iC9.GD2.CAR.IL-15 T输注，贝伐单抗，PT217，ABBV-011，AMG 404，IFIFINatamab Deruxtecan（I-DXd），IC-5404-FU，RO7616789，HPN328，BNT411，BI 764532，Chiauranib，Chiauranib，Rhenium（Re 188 P2045，BAY86-5284），89Zr-DFO-girentuximab，SY-5609，JAB，SY-5609，JAB-5609，JAB-2485，CBX-12等。

Scope of the Small-Cell Lung Cancer Market Report

小细胞肺癌市场报告的范围

Therapeutic Assessment: Small-Cell Lung Cancer current marketed and emerging therapies

治疗评估：小细胞肺癌目前市场和新兴疗法

Small-Cell Lung Cancer Market Dynamics: Conjoint Analysis of Emerging Small-Cell Lung Cancer Drugs

小细胞肺癌市场动态：新兴小细胞肺癌药物的联合分析

Competitive Intelligence Analysis: SWOT analysis and Market entry strategies

竞争智力分析：SWOT分析和市场准入策略

Unmet Needs, KOL's views, Analyst's views, Small-Cell Lung Cancer Market Access and Reimbursement

未满足的需求，KOL的观点，分析师的观点，小细胞肺癌的市场准入和报销

Discover more about small-cell lung cancer drugs in development @ Small-Cell Lung Cancer Clinical Trials

发现更多关于小细胞肺癌药物开发@小细胞肺癌临床试验

Table of Contents

目录

1.

1.

Small-Cell Lung Cancer Market Key Insights

小细胞肺癌市场关键见解

2.

2.

Small-Cell Lung Cancer Market Report Introduction

小细胞肺癌市场报告简介

3.

3.

Small-Cell Lung Cancer Market Overview at a Glance

小细胞肺癌市场概况一目了然

4.

4.

Small-Cell Lung Cancer Market Executive Summary

小细胞肺癌市场执行摘要

5.

5.

Disease Background and Overview

疾病背景和概述

6.

6.

Small-Cell Lung Cancer Treatment and Management

小细胞肺癌的治疗和管理

7.

7.

Small-Cell Lung Cancer Epidemiology and Patient Population

小细胞肺癌流行病学和患者人群

8.

8.

Patient Journey

耐心之旅

9.

9.

Small-Cell Lung Cancer Marketed Drugs

小细胞肺癌销售药物

10.

10.

Small-Cell Lung Cancer Emerging Drugs

小细胞肺癌新兴药物

11.

11.

Seven Major Small-Cell Lung Cancer Market Analysis

七大小细胞肺癌市场分析

12.

12.

Small-Cell Lung Cancer Market Outlook

小细胞肺癌市场前景

13.

13.

Potential of Current and Emerging Therapies

当前和新兴疗法的潜力

14.

14.

KOL Views

KOL Views

15.

15.

Unmet Needs

未满足的需求

16.

16.

SWOT Analysis

SWOT分析

17.

17.

Appendix

附录

18.

18.

DelveInsight Capabilities

DelveInsight功能

19.

19.

Disclaimer

免责声明

20.

20.

About DelveInsight

关于DelveInsight

Related Reports

相关报告

Small-Cell Lung Cancer Epidemiology

小细胞肺癌流行病学

Small-Cell Lung Cancer Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted small-cell lung cancer epidemiology in the 7MM.

小细胞肺癌流行病学预测-2032年报告深入了解了7MM的疾病，历史和预测的小细胞肺癌流行病学。

Small-Cell Lung Cancer Pipeline

小细胞肺癌管道

Small-Cell Lung Cancer Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key small-cell lung cancer companies, including Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, GlaxoSmithKline, Advanced Accelerator Applications, Trillium Therapeutics, Vernalis, Oncoceutics, NewBio Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, Xencor, Jiangsu HengRui Medicine, Aileron Therapeutics, Roche, Ipsen, Celgene, Lee's Pharmaceutical Limited, AbbVie, G1 Therapeutics, Chipscreen Biosciences, Luye Pharma Group, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics, among others..

小细胞肺癌管道洞察力-2023报告提供了有关管道景观，管道药物概况（包括临床和非临床阶段产品）以及关键小细胞肺癌公司（包括Ascentage Pharma，Merck＆Co，AstraZeneca，Advenchen Laboratories，GlaxoSmithKline，Advanced Accelerator Applications，Trillium Therapeutics，Vernalis，Oncoceutics，NewBio Therapeutics，Wigen Biomedicine，Linton Pharm，Carrick Therapeutics，Xencor，江苏恒瑞医药，Aileron Therapeutics，Roche，Ipsen，Celgene，Lee's Pharmaceutical Limited，AbbVie，G1 Therapeutics，Chipscreen Biosciences，Luye Pharma Group，Shanghai Henlius Biotech，CSPC中奇制药技术，Impact Therapeutics等。。

Non-small Cell Lung Cancer Pipeline

非小细胞肺癌管道

Non-small Cell Lung Cancer Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key non-small cell lung cancer companies, including BridgeBio Pharma, Daiichi Sankyo, EMD Serono, Merck, BridgeBio Pharma, Abbvie, Pfizer, Eli Lilly and Company BioNTech SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang, Bristol Myers Squibb, Innovent Biologics, Xuanzhu Biopharmaceutical, Bayer, GeneScience Pharmaceuticals, InventisBio, Apollomics, Imugene, Ono Pharmaceutical, Pierre Fabre, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb, Surface Oncology, Inhibrx, Sinocelltech, Mirati Therapeutics, REVOLUTION Medicines, Yong Shun Technology Development, Iovance Biotherapeutics, Galecto Biotech, among others..

非小细胞肺癌管道洞察力-2023报告提供了有关管道景观，管道药物概况（包括临床和非临床阶段产品）以及关键非小细胞肺癌公司的全面见解，包括BridgeBio Pharma，第一三共，EMD Serono，默克，BridgeBio Pharma，Abbvie，辉瑞，礼来和BioNTech SE公司，深圳TargetRx，Taiho Pharmaceutical，Chong-Kun Dang，Bristol-Myers Squibb，Innovent Biologics，Xuanzhu Biopharmaceutical，Bayer，GeneScience Pharmaceuticals，InventisBio，Apollomics，Imugene，Ono Pharmaceutical，Pierre Fabre，江苏恒瑞医药有限公司，Bristol-Myers Squibb，Surface Oncology，Inhibrx，Sinocelltech，Mirati Therapeutics，Iovance Biotherapeutics，Galecto Biotech等。。

Non-small Cell Lung Cancer Market

非小细胞肺癌市场

Non-small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NSCLC companies, including EMD Serono, Merck, Cellular Biomedicine Group, Inc., Celgene, CellSight Technologies, Inc., BeyondSpring Pharmaceuticals Inc., J Ints Bio, Forward Pharmaceuticals Co., Ltd., AstraZeneca, Bristol-Myers Squibb, Teligene US, Rain Oncology Inc, ReHeva Biosciences, Inc., Amgen, Novartis, RedCloud Bio, Parexel, Vitrac Therapeutics, LLC, Mythic Therapeutics, Instil Bio, Mirati Therapeutics Inc., Daiichi Sankyo, Inc., AstraZeneca, Precision Biologics, Inc, Promontory Therapeutics Inc., Palobiofarma SL, Regeneron Pharmaceuticals, Revolution Medicines, Inc., Cullinan Oncology, LLC, Iovance Biotherapeutics, Inc., Innate Pharma, among others..

非小细胞肺癌市场洞察力，流行病学和市场预测-2032年报告深入了解该疾病，历史和预测的流行病学，以及市场趋势，市场驱动因素，市场障碍和关键的NSCLC公司，包括EMD Serono，Merck，CellBiomedicine Group，Inc.，Celgene，CellSight Technologies，Inc。，BeyondSpring Pharmaceuticals Inc.，J Ints Bio，Forward Pharmaceuticals Co.，Ltd.，AstraZeneca，Bristol-Myers Squibb，Teligene US，Rain Oncology Inc，ReHeva Biosciences，Inc.，Amgen，Novartis，RedCloud Bio，Parexel，Vitrac Therapeutics，LLC，Mythic Therapeutics，Instil Bio，Mirati Therapeutics Inc.，Daiichi Sankyo，Inc.，AstraZeneca，Precision Biologics，Inc.，Promontory。，Palobiofarma SL，Regeneron Pharmaceuticals，Revolution Medicines，Inc.，Cullinan Oncology，LLC，Iovance Biotherapeutics，Inc.，Innate Pharma等。。

About DelveInsight

关于DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve..

DelveInsight是专注于生命科学的领先商业顾问和市场研究公司。它通过提供全面的端到端解决方案来支持制药公司，以提高其绩效。通过我们基于订阅的平台PharmDelve，可以轻松访问所有医疗保健和制药市场研究报告。。

Contact Us Shruti Thakur  [email protected]  +1(919)321-6187 www.delveinsight.com

联系我们Shruti Thakur[电子邮件保护]+1（919）321-6187 www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

徽标：https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP

来源DelveInsight商业研究，LLP